Survival after allo-HCT in patients with MDS/AML with TP53 loss of function and concurrent high-risk cytogenetics
| Author . | Study type . | Disease . | Pts with TP53 LOF receiving allo-HCT . | Subset with high-risk cytogenetics . | DFS from time of HCT . | OS from time of HCT . |
|---|---|---|---|---|---|---|
| MDS∗ | ||||||
| Lindsley et al25 | Registry | MDS | TP53 mut: 289 pts | Not listed | Not listed | 3-y OS: ∼15% (complex) |
| Yoshizato et al26 | Registry | MDS including subset with sAML | TP53 mut: 98 pts | Complex: 86 pts | Not listed | Median OS: 4.3 mo 3-y OS: ∼10% (complex) |
| AML | ||||||
| Middeke et al23 | Registry | AML | 17p abnl: 201 pts | Monosomal: 77 pts Complex: 180 pts | 3-y EFS: 9% (monosomal) 3-y EFS: 9% (complex) | 3-y OS: 11% (monosomal) 3-y OS: 11% (complex) |
| Middeke et al22 | 3 multicenter clinical trials | AML | TP53 mut: 40 pts | Adverse†: 40 pts | 3-y PFS: 7.5% (adverse) | 3-y OS: 10% (adverse) |
| Luskin et al27 | Single center | AML | TP53 mut: 9 pts | Adverse‡: 6 pts | All relapsed (adverse; range, 1.6-18.6 mo after HCT) | Not listed |
| Poire et al24 | Registry | AML | 17p abnl: 125 pts | Monosomal: 86 pts −5/5q-: 58 pts | 2-y: 17% (monosomal) 2-y: 11% (−5/5q-) | 2-y OS: 19% (monosomal) 2-y OS: 16% (−5/5q-) |
| Najima et al28 | Single center | AML (nonremission) | TP53 mut: 23 pts | Monosomal: 11 pts | Not listed | All died within 12 mo post allo-HCT (monosomal) |
| Grob et al18 | 4 multicenter clinical trials | MDS-EB AML | TP53 mut: 59 pts | Complex: 48 pts | Not listed | 3-y OS: ∼10% (complex) |
| Loke et al21 | Registry | AML | TP53 mut: 179 pts | 17p loss and/or complex: 126 pts | 2-y PFS: 15.2% (17p loss and/or complex) | 2-y OS: 24.6% (17p loss and/or complex) |
| Author . | Study type . | Disease . | Pts with TP53 LOF receiving allo-HCT . | Subset with high-risk cytogenetics . | DFS from time of HCT . | OS from time of HCT . |
|---|---|---|---|---|---|---|
| MDS∗ | ||||||
| Lindsley et al25 | Registry | MDS | TP53 mut: 289 pts | Not listed | Not listed | 3-y OS: ∼15% (complex) |
| Yoshizato et al26 | Registry | MDS including subset with sAML | TP53 mut: 98 pts | Complex: 86 pts | Not listed | Median OS: 4.3 mo 3-y OS: ∼10% (complex) |
| AML | ||||||
| Middeke et al23 | Registry | AML | 17p abnl: 201 pts | Monosomal: 77 pts Complex: 180 pts | 3-y EFS: 9% (monosomal) 3-y EFS: 9% (complex) | 3-y OS: 11% (monosomal) 3-y OS: 11% (complex) |
| Middeke et al22 | 3 multicenter clinical trials | AML | TP53 mut: 40 pts | Adverse†: 40 pts | 3-y PFS: 7.5% (adverse) | 3-y OS: 10% (adverse) |
| Luskin et al27 | Single center | AML | TP53 mut: 9 pts | Adverse‡: 6 pts | All relapsed (adverse; range, 1.6-18.6 mo after HCT) | Not listed |
| Poire et al24 | Registry | AML | 17p abnl: 125 pts | Monosomal: 86 pts −5/5q-: 58 pts | 2-y: 17% (monosomal) 2-y: 11% (−5/5q-) | 2-y OS: 19% (monosomal) 2-y OS: 16% (−5/5q-) |
| Najima et al28 | Single center | AML (nonremission) | TP53 mut: 23 pts | Monosomal: 11 pts | Not listed | All died within 12 mo post allo-HCT (monosomal) |
| Grob et al18 | 4 multicenter clinical trials | MDS-EB AML | TP53 mut: 59 pts | Complex: 48 pts | Not listed | 3-y OS: ∼10% (complex) |
| Loke et al21 | Registry | AML | TP53 mut: 179 pts | 17p loss and/or complex: 126 pts | 2-y PFS: 15.2% (17p loss and/or complex) | 2-y OS: 24.6% (17p loss and/or complex) |
abnl, abnormality; DFS, disease-free survival; EB, excess blasts; EFS, event-free survival; mut, mutation; LOF, loss-of-function; PFS, progression-free survival; pts, patients; sAML, secondary AML.
Included MDS-EB so long as <20% blasts.
Defined as (1) complex karyotype, (2) monosomy of chromosome 7, (3) monosomy and/or deletion of the long arm of chromosome 5, and (4) abnormalities of chromosome 17p.
Defined as 4 or more abnormalities.